Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + venetoclax with or without obinutuzumab versus chemoimmunotherapy in untreated CLL without del(17p)/TP53 mutation
CTR20190595Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of acalabrutinib, venetoclax, obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AstraZeneca. Started Mar 2021; status: active.
02
Drugs
acalabrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20190595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190595.